Following its 2021 merger with Grace Therapeutics, Acasti acquired a robust pipeline of clinical-stage assets designed to improve drug efficacy and safety through innovative delivery methods. The company has completed patient enrollment in its Phase 3 STRIVE-ON safety trial and anticipates an NDA submission to the FDA in H1 2025.
Cyborg Score Rationale
Acasti achieved the milestone of completing Phase 3 enrollment ahead of schedule. The company significantly reduced net losses in FY2024 and cut R&D expenses, demonstrating improved operational efficiency. Cash runway extending into Q2 2026 provides adequate time for regulatory readout and potential approval.
Top Insights
Phase 3 STRIVE-ON enrollment completed ahead of schedule with data readout expected in early 2025 and NDA submission planned for H1 2025.
FY2024 net loss improved to $12.9M vs. $42.4M prior year; company maintains $23M in cash as of March 2024.
2021 acquisition of Grace Therapeutics fundamentally redirected the company toward rare disease drug delivery innovations.
If approved, GTX-104 could transform the standard of care for aSAH patients by addressing oral nimodipine administration challenges.
Named Competitors
Reata Pharmaceuticals — Rare disease biopharmaceutical company developing therapies for rare neurological and metabolic disorders
Alexion Pharmaceuticals — Biopharmaceutical company focused on rare disease treatments including neurological conditions
Orphazyme — Rare disease biotech developing therapies for neurodegenerative and rare neurological disorders
Vtv Therapeutics — Biopharmaceutical company developing targeted therapies for rare neurological diseases and drug delivery innovation
Recent Developments
(September 2024) Completed patient enrollment in Phase 3 STRIVE-ON safety trial for GTX-104 ahead of schedule
(June 2024) Reported improved FY2024 financial results with $12.9M net loss, down from $42.4M in FY2023
(H1 2025 expected) Data readout from STRIVE-ON trial and planned FDA NDA submission
Open the full interactive Acasti Pharma Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.